MedTrace Logo

Pharmacological Properties of Salmeterol

NCT02558088 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2017-01-31

No results posted yet for this study

Summary

The objective of the study is to help establish a urinary threshold for salmeterol on the World Anti-doping Agency prohibited list, to avoid supratherapeutic of this substance in competitive sports.

Hence, there is no hypothesis as such.

Conditions

  • Pharmacokinetics in Healthy Young Men

Interventions

DRUG

Salmeterol

Sponsors & Collaborators

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Vibeke Backer, Professor · Bispebjerg Hospital

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02558088 on ClinicalTrials.gov